Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Sci Rep ; 13(1): 5556, 2023 04 05.
Artículo en Inglés | MEDLINE | ID: mdl-37019935

RESUMEN

Diet is the primary factor affecting host nutrition and metabolism, with excess food intake, especially high-calorie diets, such as high-fat and high-sugar diets, causing an increased risk of obesity and related disorders. Obesity alters the gut microbial composition and reduces microbial diversity and causes changes in specific bacterial taxa. Dietary lipids can alter the gut microbial composition in obese mice. However, the regulation of gut microbiota and host energy homeostasis by different polyunsaturated fatty acids (PUFAs) in dietary lipids remains unknown. Here, we demonstrated that different PUFAs in dietary lipids improved host metabolism in high-fat diet (HFD)-induced obesity in mice. The intake of the different PUFA-enriched dietary lipids improved metabolism in HFD-induced obesity by regulating glucose tolerance and inhibiting colonic inflammation. Moreover, the gut microbial compositions were different among HFD and modified PUFA-enriched HFD-fed mice. Thus, we have identified a new mechanism underlying the function of different PUFAs in dietary lipids in regulating host energy homeostasis in obese conditions. Our findings shed light on the prevention and treatment of metabolic disorders by targeting the gut microbiota.


Asunto(s)
Dieta Alta en Grasa , Grasas de la Dieta , Ratones , Animales , Dieta Alta en Grasa/efectos adversos , Grasas de la Dieta/farmacología , Obesidad/metabolismo , Ácidos Grasos Insaturados/efectos adversos , Inflamación/metabolismo , Ratones Endogámicos C57BL , Metabolismo de los Lípidos
2.
Parasitol Int ; 87: 102532, 2022 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-34933121

RESUMEN

Plasmodium falciparum, the most virulent human malaria parasite, causes serious diseases among the infected patients in the world and is particularly important in African regions. Although artemisinin combination therapy is recommended by the WHO for treatment of P. falciparum-malaria, the emergence of artemisinin-resistant parasites has become a serious issue which underscores the importance of sustained efforts to obtain novel chemotherapeutic agents against malaria. As a part of such efforts, thirty-nine herbal extracts from traditional Chinese medicine (TCM) were assayed for their anti-malarial activity using 3D7 strain of P. falciparum. Three herbal supplements appeared to possess higher specific anti-malarial activity than the others. One of them (D3) was separated by two sequential fractionations with reverse-phase (the first step) and normal-phase (the second step) liquid chromatography, in which some fractions resulted in higher specific activities than those of D3 or the previous fractions. Cell toxicity assay was performed with the fractions of the first fractionation and demonstrated no obvious cell toxicity. These results suggest that structure determination of the major compound for the anti-malarial activity in D3 may help the development of more potent chemicals in the future.


Asunto(s)
Antimaláricos/uso terapéutico , Medicamentos Herbarios Chinos/uso terapéutico , Inonotus/química , Malaria Falciparum/tratamiento farmacológico , Panax notoginseng/química , Plasmodium falciparum/efectos de los fármacos , Antimaláricos/farmacología , Antimaláricos/toxicidad , Artemisininas/farmacología , Artemisininas/uso terapéutico , Resistencia a Medicamentos , Medicamentos Herbarios Chinos/química , Medicamentos Herbarios Chinos/farmacología , Medicamentos Herbarios Chinos/toxicidad , Células HeLa , Humanos , Concentración 50 Inhibidora , Japón
3.
J Vet Med Sci ; 73(10): 1377-9, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21685719

RESUMEN

Bumped kinase inhibitors (BKIs) target analog-sensitive kinases, which the genomes of mammals rarely encode. Previously, we demonstrated that a BKI effectively suppressed the in vitro replication of Toxoplasma gondii, the causative pathogen of toxoplasmosis, by targeting T. gondii calcium-dependent protein kinase 1 (TgCDPK1) (Eukaryotic Cell, 9: 667-670). Here, we examined whether the BKI 1NM-PP1 reduced parasite replication in vivo. A high dose of 1NM-PP1, by intraperitoneal injection, just before the parasite inoculation effectively reduced the parasite load in the brains, livers, and lungs of T. gondii-infected mice, however, a low dose of 1NM-PP1 with oral administration didn't change the survival rates of infected mice.


Asunto(s)
Antiprotozoarios/uso terapéutico , Inhibidores de Proteínas Quinasas/uso terapéutico , Pirazoles/uso terapéutico , Pirimidinas/uso terapéutico , Toxoplasmosis/tratamiento farmacológico , Administración Oral , Animales , Encéfalo/parasitología , Relación Dosis-Respuesta a Droga , Femenino , Inyecciones Intraperitoneales , Hígado/parasitología , Pulmón/parasitología , Ratones , Ratones Endogámicos ICR , Carga de Parásitos , Tasa de Supervivencia , Toxoplasmosis/mortalidad , Toxoplasmosis/parasitología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA